Brammer Bio, Sarepta Enter Long-term Mfg. Tie-up

04:14 EDT 14 Jun 2018 | Contract Pharma

Partnership will provide commercial supply for a potential micro-dystrophin gene therapy product launch

Original Article: Brammer Bio, Sarepta Enter Long-term Mfg. Tie-up


More From BioPortfolio on "Brammer Bio, Sarepta Enter Long-term Mfg. Tie-up"

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...